The End of Humira’s $200 Billion Drug Monopoly
After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.
This week, what makes this prescription drug showdown so unusual – and so important.
Marta Wosińska, PhD, Visiting Fellow, Brookings Institution
Learn more and read a full transcript on our website.
Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.
Support this type of journalism today, with a gift.
Hosted on Acast. See acast.com/privacy for more information.